Combination decitabine and cedazuridine solid oral dosage forms
AssigneeOtsuka Pharmaceutical Co., Ltd.
InventorsAram Oganesian, Nipun Davar, Jim Hwaicher Kou
Life of this patent
Estimating the term…
Loading patent…
AssigneeOtsuka Pharmaceutical Co., Ltd.
InventorsAram Oganesian, Nipun Davar, Jim Hwaicher Kou
Estimating the term…
Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.
A solid oral dosage form comprising cedazuridine and decitabine, wherein the solid oral dosage form upon daily administration to a human provides plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily intravenous dose of decitabine of 20 mg/m2 administered as a 1 h infusion.
-38. (canceled)
Dependencies are inferred from the claim text.